









Markets
/
Stocks
/
nasdaq-sgmt
/

Sagimet Biosciences Inc

SGMT

5.550USD

+0.110+2.02%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

180.49MMarket Cap

LossP/E TTM



Sagimet Biosciences Inc

5.550

+0.110+2.02%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sagimet Biosciences Inc

Currency: USD Updated: 2026-02-05

Key Insights

Sagimet Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 101 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.73.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sagimet Biosciences Inc's Score

Industry at a Glance

Industry Ranking

101 / 392

Overall Ranking

226 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Sagimet Biosciences Inc Highlights

StrengthsRisks

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -3.04, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 12.74M shares, decreasing 42.73% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.74K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.37.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

24.727

Target Price

+296.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-05

The current financial score of Sagimet Biosciences Inc is 8.14, ranking 59 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.14

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.23

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.25

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Sagimet Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-05

The current valuation score of Sagimet Biosciences Inc is 6.41, ranking 286 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.04, which is -68.05% below the recent high of -0.97 and -417.27% above the recent low of -15.71.

Score

Industry at a Glance

Previous score

6.41

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 101/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-05

The current earnings forecast score of Sagimet Biosciences Inc is 8.36, ranking 131 out of 392 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 35.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.36

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

25.455

Target Price

+367.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Sagimet Biosciences Inc

SGMT

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-05

The current price momentum score of Sagimet Biosciences Inc is 6.64, ranking 153 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.75 and the support level at 4.57, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.15

Change

-0.51

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(6)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.060

Sell

RSI(14)

42.707

Neutral

STOCH(KDJ)(9,3,3)

30.954

Sell

ATR(14)

0.524

High Vlolatility

CCI(14)

-108.348

Sell

Williams %R

75.515

Sell

TRIX(12,20)

-0.124

Sell

StochRSI(14)

10.806

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

5.972

Sell

MA10

5.886

Sell

MA20

6.071

Sell

MA50

6.135

Sell

MA100

6.840

Sell

MA200

6.781

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-05

The current institutional shareholding score of Sagimet Biosciences Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 41.10%, representing a quarter-over-quarter increase of 37.37%. The largest institutional shareholder is The Vanguard, holding a total of 1.26M shares, representing 4.06% of shares outstanding, with 8.01% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

AP11 Limited

1.50M

-9.07%

Woodline Partners LP

1.50M

-41.18%

Blue Owl Capital Holdings LP

1.33M

The Vanguard Group, Inc.

Star Investors

1.20M

+4.28%

Baker Bros. Advisors LP

953.00K

Millennium Management LLC

776.38K

+926.41%

HHLR Advisors, Ltd.

724.80K

Invus Public Equities Advisors, LLC

724.77K

D. E. Shaw & Co., L.P.

701.24K

+387.49%

Schonfeld Strategic Advisors LLC

523.77K

+462.41%

Risk Assessment

Currency: USD Updated: 2026-02-05

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sagimet Biosciences Inc is 3.52, ranking 138 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.